An Ultra Fast and Sensitive Detection of 165 Drugs of Abuse in Human Urine Using Polarity Switching Ultra Performance Liquid Chromatog- Raphy Tandem Mass Spectrometry

Total Page:16

File Type:pdf, Size:1020Kb

An Ultra Fast and Sensitive Detection of 165 Drugs of Abuse in Human Urine Using Polarity Switching Ultra Performance Liquid Chromatog- Raphy Tandem Mass Spectrometry id15306796 pdfMachine by Broadgun Software - a great PDF writer! - a great PDF creator! - http://www.pdfmachine.com http://www.broadgun.com AAnnaallyyttiiccaaIlSlS N : 0974-7419 Volume 15 Issue 8 CCHHEEAMMn InIdIiSSanTT JoRuRrnYaYl Full Paper ACAIJ, 15(8) 2015 [319-338] An ultra fast and sensitive detection of 165 drugs of abuse in human urine using polarity switching ultra performance liquid chromatog- raphy tandem mass spectrometry Sachin Dubey, Shobha Ahi, Alka Beotra*, Tejinder Kaur, Shila Jain National Dope Testing Laboratory, Ministry of Youth Affairs and Sports, CGO Complex, Lodhi Road, New Delhi, 110003, (INDIA) E-mail : [email protected] ABSTRACT KEYWORDS The screening of wide variety of prohibited substances in a time bound Bioanalytical method; manner by adhering to latest World Anti-Doping Agency (WADA) guide- Sports drug testing; lines is a challenging task for doping control laboratories. The revised crite- UPLC-MS/MS; rion of detection limits (WADATD2013MRPL) has further required the doping Polarity switching; laboratories to review their testing procedures. The present work was aimed WADA. at developing a fast, sensitive and robust analytical method based on solid phase cleanup (SPE) and ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) to achieve the required detection lev- els. The method development involved optimization of deconjugation of phase II metabolites, SPE using mixed-mode ion cartridges for extraction of analytes of wider chemistries; and fast polarity switching UPLC-MS/MS detection. The developed method was validated to detect approximately 165 compounds and/or metabolites prohibited by WADA. The eight min- utes runtime allowed testing of approximately 180 samples in 24 hours at the limit of detection (LOD) of 50% below required detection levels. 2015 Trade Science Inc. - INDIA INTRODUCTION follow[2]. The prohibited list covers nine pharma- ceutical classes of substances (e.g., anabolic ste- The detection and identification of prohibited roids, corticosteroids, stimulants, diuretics, anti-es- compounds and methods of doping has been regu- trogens etc), three forbidden doping methods (e.g., lated for sports drug testing laboratories by World substance for enhancement of oxygen transfer, chemi- Anti-Doping Agency (WADA). The WADA publishes cal and physical manipulation and gene doping), and â-blockers are a prohibited list every year consisting of wide range two groups of analytes alcohol and of pharmacological classes of drugs[1]. WADA cre- prohibited in specific activities[1]. Therefore, numer- ates respective technical documents that outline mini- ous technical approaches are needed to analyse the mum required performance limits (MRPL) as well great diversity of doping agents. as international standard for laboratories (ISL), Anti-doping analysis is conducted in two steps. which accredited doping control laboratoriesmust Initially, screening of samples is performed, in the 320 An ultra fast and sensitive detection o.f 165 drugs of abuse in human urine ACAIJ, 15(8) 2015 Full Paper case of a suspiciousresult; an additional selective pre-treatment for a screening purpose is a challenge confirmation is carried out[3]. As every sample has as the method should provide good extraction yields to be screened, the screening method has to be highly for a combination of analytes with very different sensitive and specific to ensure identification of sus- physico-chemical properties (neutral, basic and pected sample and in the same time should mini- acidic, lipophilic and hydrophilic). Moreover, hu- mize the probability of false suspects. Doping analy- man urine is usually a very dirty matrix so it re- sis requires the use of several different chromato- quires an extraction technique in which the impuri- graphic, mass spectrometric and immunological ties of the sample should be eliminated to avoid any methods[4-7] which makes it mandatory for all the possible unwanted interference of the matrix. The doping control laboratories to have a number of sepa- diversified categories of drugs of abuse mostly con- rate analytical procedures, thereby making screen- tain basic compounds with exceptions of neutrals ing of each sample more complex, time-consuming (glucocorticosteroids) and acidics (diuretics). Be- and laborious. Therefore, it has become necessary sides, the huge number of different endogenous com- to develop high-throughput techniques to screen in a ponents normally found in urine makes the selective single method a large set of compounds with differ- detection of analytes at low concentration very chal- ent physicochemical properties avoiding false nega- lenging. Recently, various methods have been de- tives and false positive results. veloped to detect the banned compounds in human In the last decade, the suitability of liquid chro- urine using dilute and shoot approach[18-19]. The di- matography-tandem mass spectrometry (LC-MS/MS) lute and inject approach is certainly fast, but it does has been demonstrated as a technique of choice over not allow for the detection of analytes at very low traditional gas chromatography mass spectrometry concentrations and does not include deconjugation (GC-MS) methods for multi-target screening due to of glucuronides[20-21]. Hydrolysis is mandatory to re- the development of electrospray ionization (ESI) move the glucuronide moieties attached to several – sources which operates at atmospheric pressure[8- doping agents during phase II metabolism. Liquid 11]. This capability allows the detection of both low- liquid extraction (LLE) may be used for the sample and high-molecular weight compounds[12]. purification but it faces some pitfalls. To cover a The ultra performance liquid chromatography wide range of different drugs, two consecutive ex- (UPLC) based methods for screening analyses have tractions, one at basic and the other at acidic pH, is emerged in the anti-doping field. The advantages of required. In addition, LLE requires careful separa- µ UPLC (in which columns are packed with sub-2 tion of the phases and can be time consuming and particles operating at pressures up to 1000 bar) have tend to use large volumes of solvent. Moreover, the been demonstrated to rapidly and efficiently sepa- sample extracts are not very clean. rate drugs and related substances[13,14]. Due to the The most preferred technique for said require- reduced analysis time, peaks become very narrow ment is solid-phase extraction (SPE) as it requires and an adapted detection device is thus mandatory. less washing and cleaning steps and blocks the im- Mass spectrometers with fast scanning like triple- purities of the sample within the cartridge. A single quadrupole (QQQ) are often coupled to UPLC and or multiple-stage SPE has been applied for the used in tandem mode by monitoring ion transi- sample preparation methods in various fields of dop- tions[15,16]. Modern QQQ instruments offer very fast ing[20-22]. In particular, a single mixed-mode cartridge acquisition cycle times and polarity switching usu- is reliable for the fractionation of acid, neutral and ally expanding the number of analytes which can be basic drugs from biological samples because the detected in a single run. Numerous methods have drugs are adsorbed separately by hydrophobic or been employed in the past decade conjoining UPLC ion-exchange interaction on to the cartridge. with QQQ mass spectrometer (UPLC-MS/MS)for To ensure consistency of the measurements identification of variety of doping agents[15-17]. amongst doping control laboratories, WADA defines The choice of development of a suitable sample the MRPL, which is the concentration of a prohib- Anallyttiicall CHEAMn InIdSianT JoRurnYal ACAIJ, 15(8) 2015 Alka Beotra et al. 321 Full Paper ited substance at which the laboratories are expected fast analytical method based on multi target approach to detect the prohibited drug/s. From January 2013, reducing the burden of number of detection methods WADA has revised the MRPL criterion for the de- and analysis time 2) method sensitive enough to tection of drugs by the anti-doping laboratories achieve the detection levels. Hence, the aim of this wherein, the MRPL of various drugs has been re- work was to develop a high throughput and sensi- duced from 20-80% (TABLE 1)[23]. In addition, the tive screening method for the detection of various criteria for limit of detection (LOD) is also revised drugs at or below the WADA TD2013 MRPL. It was ’s (TDMRPL2013) which states that the laboratory required to derive the extraction procedure to ex- method validation of the initial testing procedure tract analytes with a very wide range of chemistries shall include the estimation of the LOD for each com- as well as the detection method so as to improve the pound and the estimated LOD shall not be higher LOD of drugs. than 50% of the MRPL. The revised MRPL and LOD Hence, a three step strategy was made for the criterion applicable from January 2013 has further overall improvement of the method: i) Enzymatic necessitated the need to review and revise testing hydrolysis for the deconjugation of phase II metabo- procedures in the doping laboratories to achieve the lites (glucuronides), ii) SPE using mixed mode car- targeted MRPLs. tridges for the execration of acidic, basic and neu- The lower detection limits enforced in the new tral molecules in single step and, iii) identification technical guidelines of WADA has required improv- of drugs on highly sensitive and upgraded instru- ing the existing screening method
Recommended publications
  • (200731) Hypromellose Phthalate (220824) Ibudilast
    21222122 Infrared Reference Spectra JP XVII Hypromellose Phthalate (200731) Hypromellose Phthalate (220824) Ibudilast The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) JP XVII Infrared Reference Spectra 21232123 Ibuprofen Ibuprofen Piconol Ifenprodil Tartrate The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) 21242124 Infrared Reference Spectra JP XVII Imidapril Hydrochloride Imipenem Hydrate Indapamide The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) JP XVII Infrared Reference Spectra 21252125 Indenolol Hydrochloride Indometacin Iohexol The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) 21262126 Infrared Reference Spectra JP XVII Iopamidol Iotalamic Acid Iotroxic Acid The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Drugs for Complications of Diabetes and Neuropathy and Utilization Thereof
    Europäisches Patentamt *EP001283054A1* (19) European Patent Office Office européen des brevets (11) EP 1 283 054 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC (43) Date of publication: (51) Int Cl.7: A61K 45/00, A61K 31/198, 12.02.2003 Bulletin 2003/07 A61P 3/10, A61P 25/00, A61P 9/00, A61P 13/12 (21) Application number: 01912425.4 (86) International application number: (22) Date of filing: 15.03.2001 PCT/JP01/02094 (87) International publication number: WO 01/068136 (20.09.2001 Gazette 2001/38) (84) Designated Contracting States: (72) Inventors: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU • KITAHARA, Yoshiro, Pharmaceutical Res. Lab. MC NL PT SE TR Kawasaki-shi, Kanagawa 210-8681 (JP) Designated Extension States: • MIURA, Kyoko, Pharmaceutical Res. Lab. AL LT LV MK RO SI Kawasaki-shi, Kanagawa 210-8681 (JP) (30) Priority: 17.03.2000 JP 2000076542 (74) Representative: Nicholls, Kathryn Margaret et al MEWBURN ELLIS (71) Applicant: Ajinomoto Co., Inc. York House Tokyo 104-8315 (JP) 23 Kingsway London WC2B 6HP (GB) (54) DRUGS FOR COMPLICATIONS OF DIABETES AND NEUROPATHY AND UTILIZATION THEREOF (57) There are provided a medicament excellent in ments, and the like are provided. At least one agent se- prevention, improvement, treatment, etc. of a diabetic lected from an antihypertensive agent, a vasodilating complication, and a medicament excellent in preven- agent and an anti-hyperlipidemic agent may be used at tion, improvement, treatment, etc. of a neuropathy, each the same time with the postprandial blood sugar-lower- using a postprandial blood sugar-lowering agent as an ing agent, by mixing further such at least one agent se- effective ingredient therefor.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub
    US 20110263526A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub. Date: Oct. 27, 2011 (54) NITRICOXIDE RELEASING PRODRUGS OF CD7C 69/96 (2006.01) THERAPEUTICAGENTS C07C 319/22 (2006.01) CD7C 68/02 (2006.01) (75) Inventor: Apparao SATYAM, Mumbai (IN) A6IP 29/00 (2006.01) A6IP 9/00 (2006.01) (73) Assignee: PIRAMAL LIFE SCIENCES A6IP37/08 (2006.01) LIMITED, Mumbai (IN) A6IP35/00 (2006.01) A6IP 25/24 2006.O1 (21) Appl. No.: 13/092.245 A6IP 25/08 308: A6IP3L/04 2006.O1 (22) Filed: Apr. 22, 2011 A6IP3L/2 308: Related U.S. Application Data 39t. O 308: (60) Provisional application No. 61/327,175, filed on Apr. A6IP3/10 (2006.01) 23, 2010. A6IPL/04 (2006.01) A6IP39/06 (2006.01) Publication Classification A6IP3/02 (2006.01) (51) Int. Cl. A6IP 9/06 (2006.01) A 6LX 3L/7072 (2006.01) 39t. W 308: A6 IK3I/58 (2006.01) A6IP II/08 (2006.015 A6 IK3I/55 (2006.01) A63/62 (2006.015 A6 IK 3/495 (2006.01) A6 IK 3/4439 (2006.01) (52) U.S. Cl. ........... 514/50: 514/166; 514/172: 514/217; A6 IK 3L/455 (2006.01) 514/255.04: 514/338; 514/356; 514/412; A6 IK 3/403 (2006.01) 514/420; 514/423: 514/510,536/28.53:540/67; A6 IK 3/404 (2006.01) 540/591; 544/396; 546/273.7: 546/318: 548/452: A6 IK 3/40 (2006.01) 548/500: 548/537; 549/464; 558/275 A6 IK3I/265 (2006.01) C7H 9/06 (2006.01) (57) ABSTRACT CO7I 71/00 (2006.01) CO7D 22.3/26 (2006.01) The present invention relates to nitric oxide releasing pro C07D 295/14 (2006.01) drugs of known drugs or therapeutic agents which are repre CO7D 40/12 (2006.01) sented herein as compounds of formula (I) wherein the drugs CO7D 213/80 (2006.01) or therapeutic agents contain one or more functional groups C07D 209/52 (2006.01) independently selected from a carboxylic acid, an amino, a CO7D 209/26 (2006.01) hydroxyl and a sulfhydryl group.
    [Show full text]
  • Compositions Comprising Nebivolol
    (19) TZZ ZZ__T (11) EP 2 808 015 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 03.12.2014 Bulletin 2014/49 A61K 31/34 (2006.01) A61K 31/502 (2006.01) A61K 31/353 (2006.01) A61P 9/00 (2006.01) (21) Application number: 14002458.9 (22) Date of filing: 16.11.2005 (84) Designated Contracting States: • O’Donnell, John AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Morgantown, WV 26505 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Bottini, Peter Bruce SK TR Morgantown, WV 26505 (US) • Mason, Preston (30) Priority: 31.05.2005 US 141235 Morgantown, WV 26504 (US) 10.11.2005 US 272562 • Shaw, Andrew Preston 15.11.2005 US 273992 Morgantown, WV 26504 (US) (62) Document number(s) of the earlier application(s) in (74) Representative: Samson & Partner accordance with Art. 76 EPC: Widenmayerstraße 5 09015249.7 / 2 174 658 80538 München (DE) 05848185.4 / 1 890 691 Remarks: (71) Applicant: MYLAN LABORATORIES, INC This application was filed on 16-07-2014 as a Morgantown, NV 26504 (US) divisional application to the application mentioned under INID code 62. (72) Inventors: • Davis, Eric Morgantown, WV 26508 (US) (54) Compositions comprising nebivolol (57) The active ingredients of the pharmaceutical composition described consist of nebivolol, one or more ACE inhibitors and one or more ARB. EP 2 808 015 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 808 015 A1 Description [0001] This application is a continuation-in-part of application Ser.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • I in Un Torn Untuk Ta in an Atau Mana Na Anth
    IIN UN TORN UNTUKTAUS IN20170304388A1 AN ATAU MANA NA ANTH ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017/ 0304388 A1 Chen et al. ( 43 ) Pub . Date: Oct. 26 , 2017 (54 ) NEW INDICATION OF CARDIOVASCULAR A61K 31/ 549 ( 2006 . 01 ) DRUGS FOR PREPARATION OF CANCER A61K 31 /505 (2006 .01 ) INHIBITION PHARMACEUTICAL A61K 31 / 404 ( 2006 .01 ) COMPOSITION A61K 31 / 366 ( 2006 .01 ) A61K 31 /341 ( 2006 . 01 ) (71 ) Applicant : LAUNX BIOMEDICAL CO ., LTD . , A61K 31 /216 ( 2006 .01 ) Kaohsiung ( TW ) A61K 31 / 197 (2006 .01 ) A61K 31 / 196 ( 2006 .01 ) ( 72 ) Inventors : Chiu -Hung Chen , Kaohsiung ( TW ) ; A61K 45 / 06 ( 2006 . 01 ) Show -Mei Chuang, Taichung ( TW ) ; A61K 31 / 138 ( 2006 . 01) Nai- Wan Hsiao , Taichung ( TW ) ; (52 ) U . S . CI. Ruei - Yue Liang , Taichung ( TW ) ; CPC .. .. .. .. A61K 38 /05 (2013 . 01 ) ; A61K 45 / 06 Xiao - Tong Tan , Taichung ( TW ) ( 2013 .01 ) ; A61K 31 / 7056 ( 2013 .01 ) ; A61K 31/ 55 (2013 .01 ) ; A61K 31 /549 ( 2013 .01 ) ; ( 73 ) Assignee : LAUNX BIOMEDICAL CO ., LTD ., A61K 31 /505 ( 2013 . 01 ) ; A61K 31/ 138 Kaohsiung ( TW ) (2013 . 01 ) ; A61K 31/ 366 ( 2013 . 01 ) ; A61K 31/ 341 ( 2013 .01 ) ; A61K 31/ 216 ( 2013 .01 ) ; (21 ) Appl. No. : 15 /521 , 536 A61K 31 / 197 (2013 . 01 ) ; A61K 31/ 196 ( 22 ) PCT Filed : Oct. 23 , 2015 ( 2013. 01 ) ; A61K 31/ 404 ( 2013. 01 ) ( 57 ) ABSTRACT ( 86 ) PCT No .: PCT/ CN2015 /092768 A method for treating a cancer includes administering to a $ 371 ( c ) ( 1 ) , subject in need thereof a pharmaceutical composition con ( 2 ) Date : Apr. 24 , 2017 taining a therapeutically effective amount of a cardiovascu lar drug or a pharmaceutical acceptable salt thereof.
    [Show full text]
  • In Vitro Inhibition of Breast Cancer Spheroid-Induced Lymphendothelial
    FULL PAPER British Journal of Cancer (2013) 108, 570–578 | doi: 10.1038/bjc.2012.580 Keywords: lymphendothelial intravasation; tumour spheroid; acetohexamide; nifedipin; isoxsuprine; proadifen In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen N Kretschy1,8, M Teichmann1,8, S Kopf1, A G Atanasov2, P Saiko3, C Vonach1, K Viola1, B Giessrigl1, N Huttary1, I Raab1, S Krieger1,WJa¨ ger4, T Szekeres3, S M Nijman5, W Mikulits6, V M Dirsch2, H Dolznig7, M Grusch6 and G Krupitza*,1 1Institute of Clinical Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; 2Department of Pharmacognosy, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria; 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; 4Department for Clinical Pharmacy and Diagnostics, Faculty of Life Sciences, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria; 5Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14, AKH BT 25.3, A-1090 Vienna, Austria; 6Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria and 7Institute of Medical Genetics, Medical University of Vienna, Waehringer Strasse 10, A-1090 Vienna, Austria Background: As metastasis is the prime cause of death from malignancies, there is vibrant interest to discover options for the management of the different mechanistic steps of tumour spreading. Some approved pharmaceuticals exhibit activities against diseases they have not been developed for. In order to discover such activities that might attenuate lymph node metastasis, we investigated 225 drugs, which are approved by the US Food and Drug Administration.
    [Show full text]
  • A Pharmaceutical Composition for Angiotensin Ii-Mediated Diseases
    (19) & (11) EP 2 277 520 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.01.2011 Bulletin 2011/04 A61K 31/4184 (2006.01) A61K 31/341 (2006.01) A61K 31/4245 (2006.01) A61K 31/496 (2006.01) (2006.01) (2006.01) (21) Application number: 10178599.6 A61K 31/5415 A61K 45/06 A61P 9/12 (2006.01) A61P 9/10 (2006.01) (2006.01) (2006.01) (22) Date of filing: 07.06.1994 A61P 9/00 A61P 13/12 A61P 5/00 (2006.01) A61P 17/00 (2006.01) A61P 25/00 (2006.01) A61P 25/24 (2006.01) A61P 25/28 (2006.01) A61P 25/22 (2006.01) A61P 27/06 (2006.01) (84) Designated Contracting States: (72) Inventors: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL • Inada, Yoshiyuki PT SE Hyogo 666 (JP) • Kubo, Keiji (30) Priority: 07.06.1993 JP 13552493 Osaka 562 (JP) (62) Document number(s) of the earlier application(s) in (74) Representative: Kalhammer, Georg et al accordance with Art. 76 EPC: Lederer & Keller 07014995.0 / 1 844 774 Patentanwälte 03001570.5 / 1 306 089 Prinzregentenstrasse 16 94108687.8 / 0 628 313 D-80538 München (DE) (71) Applicant: Takeda Pharmaceutical Company Remarks: Limited This application was filed on 23-09-2010 as a Osaka 541-0045 (JP) divisional application to the application mentioned under INID code 62. (54) A pharmaceutical composition for angiotensin ii-mediated diseases (57) This invention relates to a pharmaceutical com- wherein R1 is H or an optionally substituted hydrocarbon position for angiotensin mediatedII- diseases, which residue; R2 is an optionally esterified carboxyl group; R 3 comprises a compound having
    [Show full text]
  • Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2020 Anatomical Classification Guidelines V2020 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2020 Anatomical Classification Guidelines V2020 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 35 D DERMATOLOGICALS 50 G GENITO-URINARY SYSTEM AND SEX HORMONES 57 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 65 J GENERAL ANTI-INFECTIVES SYSTEMIC 69 K HOSPITAL SOLUTIONS 84 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 92 M MUSCULO-SKELETAL SYSTEM 102 N NERVOUS SYSTEM 107 P PARASITOLOGY 118 R RESPIRATORY SYSTEM 120 S SENSORY ORGANS 132 T DIAGNOSTIC AGENTS 139 V VARIOUS 141 Anatomical Classification Guidelines V2020 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]